MarketCapExport financials
Puma Biotechnology (PBYI)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Puma Biotechnology Financial Ratios 2025-2010 | PBYI
Brief overview of Puma Biotechnology's valuation multiples
Current figures are compared with the company's own five-year history for 2021–2025.
Market valuation is represented by P/E 12.15x (median 12.85x), EV/EBITDA 9.01x (median 8.89x), P/S 1.66x (median 0.76x). Ratios sit near their own comparison base, with an average deviation of 0% from five-year medians.
Earnings yield calculated as 1/P/E is about 8.2%, showing current profit per unit of share price.
The latest available business-quality ratios are ROE 23.9%, ROA 14.4%, ROCE 28.6%. Returns on capital and assets point to efficient economics and a strong internal source of growth.
PEG is 6.48x. Price is well ahead of embedded growth, making market expectations demanding.
The cash conversion cycle increased 74.5 days to 80 days, weakening working-capital efficiency.
Conclusion
Puma Biotechnology's market valuation is near its own historical norm, while quality ratios provide no extreme signal.
Annual Financial Ratios Puma Biotechnology
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 12.2 | 4.8 | 13.6 | 87115.3 | -4.2 | -6.8 | -4.2 | -9.0 | -8.4 | -3.7 | -5.6 | -44.6 | -65.2 | -7.1 | - | - | |
P/S |
1.7 | 0.6 | 1.2 | 0.8 | 0.5 | 1.8 | 1.2 | 4.1 | 88.3 | - | - | - | - | - | - | - |
EPS |
0.6 | 0.6 | 0.5 | - | -0.7 | -1.5 | -75595 | -3.0 | -7.8 | -8.3 | -7.5 | -4.7 | -1.9 | -3.4 | -1.3 | -0.0 |
EV (Enterprise Value) |
434 M | 197 M | 385 M | 298 M | 289 M | 571 M | 471 M | 1.14 B | 2.47 B | 869 M | 1.34 B | 6.34 B | 3.54 B | 412 M | -52.4 M | - |
EBITDA per Share |
0.96 | 0.87 | 0.94 | 0.75 | 0.31 | -0.51 | -0.77 | -2.3 | -7.79 | -8.27 | -7.46 | -4.72 | -1.9 | -3.41 | - | - |
EV/EBITDA |
9.0 | 4.6 | 8.7 | 8.9 | 24.2 | -23.4 | -11.7 | -12.2 | -8.3 | -3.0 | -5.5 | -44.4 | -64.7 | -5.3 | - | - |
PEG |
6.48 | -0.69 | -0.72 | -2297.34 | 0.06 | 0.2 | -0.12 | -0.15 | -1.58 | 0.33 | 0.1 | 0.3 | -1.47 | 0.04 | - | - |
P/B |
2.9 | 1.6 | 5.5 | 8.1 | -50.5 | -68.2 | 18.0 | 29.9 | 45.9 | 4.9 | 6.5 | 54.1 | 42.5 | 4.1 | - | - |
P/CF |
9.0 | 3.7 | 10.8 | -11.0 | 6.0 | 525.3 | 14.2 | -41.5 | -11.0 | -6.9 | -8.6 | -80.7 | -64.0 | -11.7 | - | - |
ROE % |
23.87 | 32.87 | 40.40 | 0.01 | 1190.76 | 1008.15 | -432.89 | -331.06 | -547.74 | -131.54 | -116.15 | -121.29 | -65.08 | -57.68 | - | - |
ROA % |
14.38 | 14.19 | 9.37 | 0.00 | -12.85 | -24.57 | -32.18 | -43.83 | -176.38 | -109.19 | -99.77 | -87.22 | -52.37 | -49.01 | - | - |
ROCE % |
28.62 | 33.61 | 61.08 | 109.77 | -52.74 | 510.87 | -26.32 | -49.31 | -272.79 | -128.45 | -115.85 | -120.25 | -64.43 | -57.27 | - | - |
Current Ratio |
2.5 | 1.8 | 1.3 | 1.1 | 1.0 | 1.0 | 1.8 | 3.0 | 1.8 | 6.3 | 6.9 | 3.4 | 5.0 | 6.9 | - | - |
DSO |
68.5 | 63.2 | 68.3 | 58.3 | 41.9 | 44.1 | 38.7 | 31.9 | 127.5 | - | - | - | - | - | - | - |
DIO |
44.7 | 44.8 | 33.8 | 38.5 | 30.3 | 30.7 | 31.4 | 27.7 | 132.9 | - | - | - | - | - | - | - |
DPO |
33.2 | 35.1 | 38.8 | 58.3 | 66.6 | 144.9 | 190.2 | 218.1 | 1814.0 | - | - | - | - | - | - | - |
Operating Cycle |
113.1 | 108.0 | 102.1 | 96.9 | 72.1 | 74.8 | 70.2 | 59.6 | 260.4 | - | - | - | - | - | - | - |
Cash Conversion Cycle |
80.0 | 72.9 | 63.3 | 38.5 | 5.5 | -70.0 | -120.0 | -158.5 | -1553.6 | - | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Financial Ratios Puma Biotechnology
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
0.16 | -0.07 | 0.18 | 0.12 | 0.06 | - | 0.41 | -0.09 | -0.1 | - | 0.12 | 0.05 | 0.03 | - | -0.01 | 0.21 | -0.08 | - | -1.09 | -0.13 | 0.41 | -0.38 | -0.79 | 0.09 | -0.43 | -0.29 | -0.44 | -0.97 | -0.26 | -0.8 | -0.37 | -1.17 | -0.65 | -1.71 | -2.07 | -2.1 | -1.97 | -2.04 | -2.02 | -2.05 | -2.19 | -1.9 | -1.87 | -2.01 | -1.66 | -1.57 | -1.19 | -1.29 | -0.67 | -0.55 | -0.5 | -0.44 | -0.41 | -0.83 | -1.29 | -0.74 | -0.59 | - | -0.09 | -0.009 | -0.001 |
EBITDA per Share |
0.25 | -0.02 | 0.19 | 0.14 | 0.14 | - | 0.45 | -0.04 | 0.01 | - | 0.18 | 0.11 | 0.16 | - | 0.06 | 0.27 | 0.04 | - | -0.02 | -0.41 | 0.57 | - | -0.13 | 0.29 | -0.31 | - | -0.21 | -0.56 | 0.31 | - | -0.16 | -1.01 | -0.58 | - | -2.04 | -2.1 | -1.97 | - | -2.01 | -2.03 | -2.19 | - | -1.86 | -2.01 | -1.66 | - | -1.18 | -1.28 | -0.67 | - | -0.49 | -0.44 | -0.41 | - | -1.29 | -0.73 | -0.59 | - | -0.08 | -0.01 | - |
ROE % |
16.25 | 13.40 | 44.91 | 27.90 | 12.86 | 9.80 | 24.76 | 3.17 | 17.93 | 27.37 | 25.75 | 58.27 | 3.64 | -1.78 | 407.23 | 391.53 | 444.61 | 492.24 | 744.19 | 863.89 | 824.16 | 1008.15 | 692.06 | 66.67 | -90.58 | -432.89 | -458.23 | -402.93 | -317.86 | -331.06 | -361.81 | -465.21 | -482.00 | -547.74 | -462.15 | -348.70 | -234.42 | -131.54 | -126.87 | -124.85 | -124.52 | -116.15 | -126.76 | -128.06 | -129.84 | -121.29 | -99.71 | -134.16 | -166.06 | -214.23 | -212.24 | -204.84 | -197.43 | -190.03 | -191.85 | -153.00 | -114.14 | -56.46 | -18.82 | -18.82 | -18.82 |
ROA % |
9.66 | 6.93 | 18.08 | 11.52 | 6.26 | 4.75 | 7.59 | -0.55 | 2.37 | 4.62 | 4.44 | -0.10 | -20.90 | -21.62 | -23.58 | -23.40 | -17.01 | -15.32 | -21.45 | -14.60 | -11.24 | -24.57 | -23.19 | -17.50 | -34.82 | -32.18 | -39.26 | -37.55 | -38.73 | -43.83 | -70.70 | -111.84 | -141.76 | -176.38 | -166.41 | -145.81 | -125.13 | -109.19 | -106.18 | -105.34 | -105.97 | -99.77 | -103.21 | -100.04 | -96.93 | -87.22 | -73.33 | -103.67 | -132.18 | -172.38 | -171.55 | -168.19 | -164.84 | -161.48 | -165.51 | -134.97 | -104.43 | -55.41 | -18.47 | -18.47 | -18.47 |
ROCE % |
17.14 | 15.76 | 49.80 | 37.01 | 26.16 | 22.06 | 44.22 | 29.25 | 50.63 | 55.14 | 65.94 | 104.87 | 78.32 | 61.44 | 143.42 | 76.17 | 137.65 | 148.10 | 351.95 | 150.18 | 446.09 | 323.53 | 240.79 | -110.68 | 65.50 | -173.97 | -206.85 | -244.92 | -165.49 | -221.88 | -367.17 | -480.96 | -497.49 | -429.30 | -460.75 | -347.15 | -234.43 | -97.09 | -126.57 | -126.63 | -120.48 | -86.52 | -117.25 | -121.00 | -106.43 | -80.89 | -97.96 | -82.36 | -63.18 | -46.25 | -66.32 | -60.72 | -54.78 | -40.73 | -41.34 | -21.33 | -9.88 | -0.68 | -0.61 | -0.06 | -0.01 |
Current Ratio |
3.6 | 3.0 | 2.3 | 2.2 | 2.0 | 1.8 | 1.5 | 1.3 | 1.3 | 1.3 | 1.2 | 1.2 | 1.1 | 1.1 | 1.1 | - | 1.0 | 1.0 | 0.9 | 1.1 | 1.1 | 1.0 | 1.0 | 1.0 | 1.0 | 1.1 | 1.1 | 1.1 | 1.1 | 1.1 | 1.1 | 1.1 | 1.1 | 1.5 | 1.5 | 1.5 | 1.5 | 5.9 | 5.9 | 5.9 | 5.9 | 7.1 | 7.1 | 7.1 | 7.1 | 3.6 | 3.6 | 3.6 | 3.6 | 5.1 | 5.1 | 5.1 | 5.1 | 6.7 | 6.7 | 6.7 | 6.7 | 54.0 | 54.0 | 54.0 | 54.0 |
DSO |
48.8 | 61.0 | 49.8 | 44.5 | 56.7 | - | 46.9 | 51.1 | 75.5 | - | 49.0 | 52.2 | 61.8 | - | 22.4 | 20.7 | 59.4 | - | 53.6 | 48.5 | 24.0 | 44.4 | 45.9 | 33.0 | 48.5 | 41.9 | 46.8 | 48.9 | 22.9 | 26.7 | 30.3 | 37.3 | 20.9 | 40.8 | 145.2 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DIO |
80.5 | 79.5 | 67.7 | 64.3 | 75.5 | - | 18.4 | 69.1 | 60.3 | - | 45.7 | 44.3 | 29.1 | - | 19.9 | 22.3 | 60.5 | - | 65.8 | - | 17.3 | - | 31.7 | - | - | - | - | 31.1 | 33.1 | - | 26.5 | 27.1 | 33.3 | - | 121.3 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DPO |
41.2 | 63.7 | 44.3 | 42.5 | 49.9 | - | 32.9 | 96.2 | 67.4 | - | 44.1 | 63.0 | 51.9 | - | 54.5 | 22.7 | 78.2 | - | 138.5 | - | 35.1 | - | 110.8 | - | - | - | - | 187.9 | 227.8 | - | 208.6 | 213.7 | 345.8 | - | 1655.9 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Cycle |
- | - | 117.5 | 108.8 | 132.2 | - | 65.2 | 120.2 | 135.8 | - | 94.7 | 96.6 | 90.9 | - | 42.3 | 43.0 | 120.0 | - | 119.4 | 48.5 | 41.3 | 44.4 | 77.6 | 33.0 | 48.5 | 41.9 | 46.8 | 80.0 | 56.0 | 26.7 | 56.7 | 64.5 | 54.1 | 40.8 | 266.5 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash Conversion Cycle |
- | - | 73.3 | 66.3 | 82.4 | - | 32.3 | 24.0 | 68.4 | - | 50.6 | 33.5 | 39.0 | - | -12.2 | 20.3 | 41.8 | - | -19.1 | 48.5 | 6.2 | 44.4 | -33.2 | 33.0 | 48.5 | 41.9 | 46.8 | -107.9 | -171.8 | 26.7 | -151.9 | -149.3 | -291.6 | 40.8 | -1389.4 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Multiples are an important financial analysis tool for the company Puma Biotechnology, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.
Advantages of Using Financial Ratios- Simplified Data Analysis
Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition. - Comparability Between Companies
Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations. - Identification of Trends and Issues
Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks. - Decision Support
Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions. - Accelerated Assessment of Investment Attractiveness
Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.
Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.
USA
Danmark
China
Britain
Australia
Israel
Germany
Canada
Russia
